Nitrolinoleate, a nitric oxide-derived mediator of cell function: Synthesis, characterization, and vasomotor activity

Transcription

1 Nitrolinoleate, a nitric oxide-derived mediator of cell function: Synthesis, characterization, and vasomotor activity Dong Gun Lim*, Scott Sweeney*, Allison Bloodsworth*, C. Roger White, Phillip H. Chumley*, N. Rama Krishna, Francisco Schopfer*, Valerie B. O Donnell, Jason P. Eiserich, and Bruce A. Freeman* ** Departments of *Anesthesiology, Biochemistry and Molecular Genetics, Medicine, and UAB Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, United Kingdom; and Department of Medicine, University of California, Davis, CA Edited by Louis J. Ignarro, University of California School of Medicine, Los Angeles, CA, and approved September 30, 2002 (received for review July 10, 2002) Nitric oxide ( NO) and NO-derived reactive species rapidly react with lipids during both autocatalytic and enzymatic oxidation reactions to yield nitrated derivatives that serve as cell signaling molecules. Herein we report the synthesis, purification, characterization, and bioactivity of nitrolinoleate (LNO 2 ). Nitroselenylation of linoleic acid yielded LNO 2 that was purified by solvent extraction, silicic acid chromatography, and reverse-phase HPLC. Structural characterization was performed by IR spectroscopy, 15 N-NMR, LC-negative ion electrospray mass spectroscopy (MS), and chemiluminescent nitrogen analysis. Quantitative MS analysis of cell and vessel LNO 2 metabolism, using L[ 15 N]O 2 as an internal standard, revealed that LNO 2 is rapidly metabolized by rat aortic smooth muscle (RASM) monolayers and rat thoracic aorta, resulting in nitrite production and up to 3-fold increases in cgmp (ED M for RASM, 50 M for aorta). LNO 2 induced endothelium-independent relaxation of preconstricted rat aortic rings, which was unaffected by L G -nitro-l-arginine methyl ester addition and inhibited by the guanylate cyclase inhibitor 1H- [1,2,4] oxadiazole[4,3-a]quinoxalin-1-one and the NO scavenger HbO 2. These results reveal that synthetic LNO 2, identical to lipid derivatives produced biologically by the reaction of NO and NO-derived species with oxidizing unsaturated fatty acids (e.g., linoleate), can transduce vascular signaling actions of NO. Nitric oxide ( NO) manifests diverse physiologic and pathologic actions beyond regulation of vascular relaxation, including the modulation of neurotransmission, inflammatory reactions, and cell proliferation (1). For example, NO inhibits platelet function and leukocyte adherence to the vessel wall via stimulation of guanylate cyclase (GC)-mediated synthesis of cgmp (1, 2). NO signaling is dictated in large part by heme protein reactions, with oxygen- and sulfur-dependent reactions of NO also of significance in the transduction and termination of NO bioactivity. For example, the reaction of NO with thiol derivatives, molecular oxygen, lipid radicals, and superoxide (O 2 ) has a profound effect on NO half-life, reactivity, and signaling properties. Secondary products of these reactions, including nitrite (NO 2 ), nitrito, nitrate ester, nitroso, and other nitrogen oxide derivatives can also activate GC after spontaneous decomposition, metabolism to NO, or the formation of heme iron-reactive redox intermediates of NO (3). Reactions of NO with oxygen-derived species also yield products expressing non-cgmp-dependent actions. NO reacts with oxygen to yield nitrogen dioxide ( NO 2 )( NO 2, k M 2 s 1 ), which in turn may further react with NO to yield nitrogen trioxide (N 2 O 3 ), a reaction that is accelerated in membranes and lipoproteins (4, 5). Peroxynitrite (ONOO ), formed from the diffusion-limited reaction of O 2 with NO (k M 1 s 1 ), is a strong oxidant that mediates oxidation, nitrosation, and nitration reactions (6, 7). In terms of NO signaling, ONOO formation (i) diverts NO away from direct GC activation (8, 9); (ii) directly activates GC (10); and (iii) reacts with biomolecules including uric acid, glucose, and glycerol to yield nitro- (RNO 2 ) and nitrito- (RONO) adducts that display NO-donating properties (11, 12). Acidic ph conditions will also protonate NO 2 (pka 3.25), a predominant byproduct of aerobic NO decomposition, to yield a series of reactive intermediates (13, 14). In aggregate, the aqueous and aerobic reactions of NO in biological milieu yield a rich spectrum of potent nitrosating, nitrating, and oxidizing products that transduce NO signaling (3). The reactions of NO and its products in hydrophobic tissue compartments are important elements in the contribution of NO to cell signaling and tissue pathobiology. Due to its small molecular radius and uncharged nature, the lipophilic NO readily diffuses through both the hydrophilic surface and the more hydrophobic core of membranes and lipoproteins, with a diffusion coefficient of up to cm 2 s 1 (15, 16). There, NO concentrates up to 20-fold and is more rapidly consumed by reaction with the molecular oxygen that also preferentially partitions in this compartment. This molecular lens effect, induced by NO and O 2 solvation in hydrophobic cell compartments, yields secondary NO-derived species capable of oxidation, nitrosation, and nitration reactions (5). The catalysis of NO oxidation may also occur in hydrophobic regions of proteins such as albumin (17). NO displays potent antioxidant and -tocopherol-preserving actions by terminating propagation reactions catalyzed by both free- and enzyme-bound lipid alkoxyl and peroxyl radical intermediates (k M 1 s 1 ), yielding nitrated products (18 22). As with the nitration and nitrosation of amino acids and DNA bases observed in a variety of inflammatory diseases, multiple mechanisms account for the nitration of lipids by NO-derived species such as NO 2, ONOO, and HNO 2 (22). During inflammatory conditions, lipid oxidation frequently occurs at an accelerated rate, yielding radical species that can serve as intermediates in lipid nitration. In acidic conditions, protonation of NO 2 to HNO 2 can mediate the nitration of polyunsaturated fatty acids and lipid hydroperoxides. Also, ONOO has been observed to readily diffuse through membranes and lipoproteins to induce nitration of unsaturated fatty acids (23, 24). Nitronium ion (NO 2 ) and NO 2 reaction with unsaturated fatty acids and the caged radical rearrangement of lipid peroxyl radical- NO reaction intermediates can yield nitrated lipid products whose structure and function are incompletely characterized (24 26). Finally, peroxidases such as myeloperoxidase This paper was submitted directly (Track II) to the PNAS office. Abbreviations: ODQ, 1H-[1,2,4] oxadiazole[4,3-a]quinoxalin-1-one; GC, guanylate cyclase; LNO 2, nitrolinoleate; MPO, myeloperoxidase; PGHS, prostaglandin H synthase; RASMC, rat aortic smooth muscle cells; MS, mass spectroscopy. Permanent address: Department of Anesthesiology, School of Medicine, Kyungpook National University, Daegu , Korea. **To whom correspondence should be addressed. bruce.freeman@ccc.uab.edu. BIOCHEMISTRY cgi doi pnas PNAS December 10, 2002 vol. 99 no

2 (MPO) can oxidize NO 2 to NO 2, a species capable of catalyzing biomolecule nitration (27, 28). Herein, we report the synthesis, purification, and characterization of a nitrated lipid, nitrolinoleate (LNO 2 ), that is structurally similar to products of the reaction of NO 2, ONOO, HNO 2, and MPO-catalyzed nitration of linoleic acid. The bioactivity of this nitrated lipid was investigated, revealing rapid metabolism by both smooth muscle cells and aortic segments to a species that yields NO 2 and stimulates cgmp production in both rat aortic smooth muscle cell (RASMC) monolayers and isolated rat thoracic aorta. The GC-activating property of LNO 2 induced relaxation of isolated rat thoracic aorta via an 1H-[1,2,4] oxadiazole[4,3-a]quinoxalin-1-one (ODQ)- and HbO 2 -inhibitable mechanism, indicating that cgmp-dependent vasomotor actions of NO can in part be transduced via the generation of nitrated fatty acids. Experimental Procedures Structural Analysis of LNO 2. The synthesis of LNO 2 via nitroselenylation (29, 30) is published as supporting information on the PNAS web site, Mass spectroscopic analysis was performed on an API III triple-quadrupole mass spectrometer (PE-Sciex, Concord, ON, Canada) after reverse-phase HPLC on (i) a mm i.d. Aquapore C 8 column (Perkin Elmer) with a linear % CH 3 OH gradient in 1% aqueous acetic acid at 0.2 ml min. Under these conditions, nitration products with either m z 324 or 340 eluted separately as single peaks, enabling integration and normalization with an added L[ 15 N]O 2 internal standard; or (ii) a mm i.d. 5- m C 18 column (Microsorb, Rainin, MA) using a gradient of 50 90%BinA(A is 75:25:0.1 H 2 O acetonitrile acetic acid; B is 60:40:0.1 CH 3 OH acetonitrile acetic acid) over 20 min at a flow rate of 1ml min. The column eluent was split, with one-tenth going to the ionspray interface. Negative ion mass spectra were recorded with an orifice potential of 60 V. Daughter ion mass spectra were obtained by selecting the parent molecular ion with the first quadrupole, colliding it with a mixture of 10% N 2 90% Ar in the second quadrupole and analyzing fragment ions in the third quadrupole. For 15 N-NMR analysis, L[ 15 N]O 2 was dissolved in 500 l of CH 3 OH d4. The spectrum was collected on a Bruker (Billerica, MA) AVANCE-600 spectrometer with the following acquisition parameters: 12,168 scans; 5-s recycle time; composite-pulse decoupling during the acquisition time (0.44 s); 25 pulse width; 37,037-Hz spectral width; and 300 K. Results are displayed as the chemical shift, and not chemical shielding, which has the opposite sign. Chemical shifts were referenced to 10% nitromethane in CH 3 OH. The 15 N sensitivity of the AVANCE-600 NMR system was confirmed by using a solution of nitromethane in CH 3 OH. NMR data were further processed by using ORIGIN graph-fitting software from OriginLab (Northampton, MA). IR spectra were recorded for LNO 2 by using a Bomem Michelson MB Series Fourier transform IR spectrometer (ABB Bomem, Quebec, Canada). LNO 2 (5 mg) was solvated in 500 l of diethyl ether and distributed on a salt plate. The solvent was evaporated with a stream of nitrogen, and the spectrum was recorded. Re-extraction and rechromatography of LNO 2 revealed no modification of the lipid derivative by analysis procedures. Nitration of Linoleic Acid by MPO. Linoleic acid (2 mm) was emulsified in 50 mm phosphate buffer 100 M diethylenetriaminepentaacetic acid, ph 5, by sonicating 3 20 sec at 1-min intervals. Human MPO (50 g) and 50 MNO 2 were added and reactions in 1 ml were initiated by addition of 100 M H 2 O 2 at 37 C four times over 1 h. Lipids were extracted, dissolved in MeOH, and subjected to HPLC fractionation with diode array and nitrogen monitoring. LNO 2 Metabolism and Signaling. LNO 2 metabolism was determined in cell suspensions prepared from confluent 75-cm 2 RASM monolayers maintained in Hanks balanced salt solution (HBSS). After addition of 10 M LNO 2 solvated in CH 3 OH ( 0.5% final CH 3 OH) for 0 60 min, reactions were terminated by addition of CHCl 3 CH 3 OH (1:1, vol vol) and heating at 60 C for 5 min. Then, 10 ML[ 15 N]O 2 was added as an internal standard. Lipids were extracted with CHCl 3 CH 3 OH H 2 O, 1:1:0.9 (vol vol), the organic phase collected, dried under a stream of N 2 gas, redissolved in CH 3 OH, and the ratio L[ 14 N]O 2 L[ 15 N]O 2 determined by negative ion-mode MS. For vessel studies, adult male Sprague Dawley rats weighing g were used (Harlan Laboratories, Indianapolis, IN), with experimental procedures approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee. Descending thoracic aortas were excised, adhering tissue dissected away, and individual ring segments (4 mm) obtained. Ring segments were cut longitudinally and in some cases the endothelium removed by gentle scraping. LNO 2 (50 M) incubation and extraction conditions were as for RASMC monolayers, except Krebs Henseleit buffer (NaHCO NaCl 118 KCl 4.7 MgSO NaH 2 PO CaCl glucose 5.6 mm, ph 7.4) was substituted for HBSS. Additional Experimental Methods. Description of materials and experimental procedures for cell culture, cgmp determination, vascular relaxation measurement, and statistical analysis are published as supporting information on the PNAS web site. Results Synthesis and Characterization of LNO 2. The nitroselenylation of linoleate yielded both nitration and peroxidation products that were purified to an LNO 2 -enriched fraction by solvent extraction and silica gel chromatography. Then, reverse-phase HPLC further resolved LNO 2 and removed all non-nitrated contaminating lipids. The fraction eluting at 18 min (Fig. 1A) was retained for subsequent study, giving m z 324 by negative ion mode electrospray MS, 45 mass units greater than the parent compound linoleate, m z 279, inferring the addition of a nitro (NO 2 )- group (Fig. 1B). Tandem MS (MS MS) yielded a daughter ion with m z 46, supporting the addition of NO 2 (Fig. 1B Inset). Analysis of products formed when substituting Na[ 15 N]O 2 for AgNO 2 in LNO 2 synthesis further verified NO 2 addition to linoleate, with L[ 15 N]O 2 yielding an ion m z 325 with a daughter ion of m z 47 by MS MS (Fig. 1C). Elemental analysis also supported incorporation of a NO 2 functional group into linoleate (not shown). The molar yield of LNO 2 from nitroselenylation of linoleate was typically 5 7%, as quantified by chemiluminescent nitrogen analysis. This species shared similar chromatographic and mass spectral properties to linoleate nitration products formed by MPO-catalyzed oxidation of NO 2 (Fig. 1A) and LNO 2 species produced by ischemic, reperfused rodent liver (unpublished observations). IR Spectroscopic Analysis of the HPLC-Purified m z 324 LNO 2 Fraction. This analysis affirmed the identification of a nitro (LNO 2 ) derivative of 18:2 and eliminated the presence of possible nitrito (LONO) or nitrate ester (LONO 2 ) products. The IR spectrum of LNO 2, when compared with that of 18:2, revealed absorbance maxima at 1,522 and 1,334 cm 1 (Table 1), corresponding to the asymmetric and symmetric stretches of nitroalkene N O bonds (30). No absorbance occurred in the 1,610 1,680 cm 1 region where the N O bonds of organic nitrites, and nitrates strongly absorb (31). When phosphatidylcholine is exposed to gaseous dinitrogen pentoxide (N 2 O 5 ), bands appear at 1,640 and 1,550 cm 1, indicative of the asymmetric N O bonds of RONO 2 and RNO 2, respectively (32), confirming the assignment herein of 1,522 cm 1 to the asymmetric N O stretch of LNO 2. The UV cgi doi pnas Lim et al.

3 Fig. 1. Purification and analysis of LNO 2.(A) Reverse-phase HPLC elution profiles of LNO 2 generated by nitroselenylation (SYN) and exposure of linoleic acid (18:2) to MPO H 2 O 2 NO 2 (MPO). Reverse-phase HPLC resolved the major nitrated linoleate derivative of m z 324, eluting at a retention time of 18 min, with parallel UV and nitrogen detection confirming the presence of nitrated fatty acid. Control reactions omitting MPO revealed no detectable nitrated products. (B and C) Electrospray MS and MS MS of LNO 2 (B) and L[ 15 N]O 2 (C). The principal LNO 2 -containing HPLC-resolved fraction in A was analyzed by negative ion mode electrospray MS and yielded a molecular ion m z 324, indicative of LNO 2.(Inset) The MS MS fragmentation pattern of the m z 324 ion yielded a daughter ion, m z 46, indicative of an NO 2 functional group. L[ 15 N]O 2 yielded an ion m z 325 with a daughter ion of m z 47 by MS MS (C). (D) 15 N NMR spectrum of LNO N NMR analysis of LNO 2 gave a doublet chemical shift indicative of at least two positional isomers. absorbance spectrum of 0.1 mm LNO 2 showed absorbance at 270 nm and max 202 nm, corresponding to aliphatic nitro compounds, whereas alkyl nitrites absorbed at 228 nm and have a low-intensity transition with six vibrational fine structure bands centered at 375 nm (not shown; ref. 33). Additional structural insight was obtained by comparison of the HPLC-purified LNO 2 fraction with the 15 N-NMR spectrum of nitromethane (Fig. 1D). Again, 15 N-NMR supported LNO 2 formation over that of LONO. LNO 2 had chemical shifts at 3.9 and 4.6 ppm (Fig. 1D) when externally referenced to nitromethane (0 ppm), suggesting the presence of positional isomers. If a nitrito derivative (LONO) were present, a distinct chemical shift would have appeared at 200 ppm (34). Metabolism and Signaling Actions of LNO 2. When added to RASMC monolayers or rat aortic segments in the dark, LNO 2 (10 and 50 M, respectively) was rapidly metabolized (Fig. 2 A and B). Fig. 2. Metabolism of LNO 2 by smooth muscle cell monolayers (A) and isolated rat thoracic aorta (B). LNO 2 (10 M) was added as an ethanolic solution to the media of RASMC in HBSS, ph 7.4, 37 C(A) and in 50 M concentration to 20 mg (wet weight) rat aortic vessel segments in Krebs Henseleit buffer, ph 7.4, 37 C(B). Values are expressed as the proportional decrease in LNO 2 at different incubation times to an L[ 15 N]O 2 internal standard added at the time of reaction termination. (C) NO 2 production by RASMC after 1-h incubation with LNO 2. For A, data represent the mean of duplicate determinations of a representative experiment repeated three times (B and C). Data represent mean SEM, n 3. There was also a LNO 2 concentration-dependent increase in medium NO 2 content after incubation of RASMC with LNO 2, with 10 20% yields of NO 2 as a function of added LNO 2 BIOCHEMISTRY Table 1. IR spectroscopic analysis of linoleate and LNO 2, units cm 1 Functional group stretch Linoleate LNO 2 Theoretical* Phosphatidylcholine N O of nitro (symmetric), RNO 2 1,334 1,360 1,290 N O of nitro (asymmetric), RNO 2 1,522 1,550 1,500 1,550 N O of nitrate, RONO 2 1,660 1,625 1,640 N O of nitrito, RONO 1,680 1,610 OH of carboxylic acid 3,000 3,000 C O 1,697 1,708 1,740 C H 2,923, 2,854 2,929, 2,858 2,850 2,940 C C 1,461, 1,413 1,462, 1,413 1,410 1,470 *From ref. 31. From ref. 32. Lim et al. PNAS December 10, 2002 vol. 99 no

4 Fig. 3. LNO 2 induces cgmp synthesis by RASMC monolayers (A) and rat thoracic aorta segments (B) in a concentration-dependent manner. Data are expressed as mean SEM, n 3, except for endothelium( ) aorta treated with 50 M LNO 2 and endothelium( ) aorta treated with 10 M SNP, where n 2. In A, * represents P 0.05, for RASMC monolayers vs. control conditions (addition of 0.05% CH 3 OH). In B, * and represent P 0.05 vs. control conditions [* for endothelium( ) and for endothelium( ) aortic segments]. observed after 1-h incubation (Fig. 2C). The release of NO by LNO 2 -treated cells and vessel segments was not detectable via electrochemical analysis having a limit of detection of 10 nm NO. Control studies showed no decay of LNO 2 in buffer alone at 37 C over similar time periods and no impact of light on LNO 2 stability. Within 5 min, LNO 2 was 50% consumed by both RASMC and aortic segments (Fig. 2 A and B), despite the temporal limitations dictated by the requirement for added LNO 2 to diffuse to and become incorporated by vascular cells before metabolism. Saponification, extraction of cell lipids 10 min after LNO 2 addition, and MS analysis did not reveal LNO 2 esterification into more complex lipids over this time period. The stability of purified LNO 2 to the alkaline conditions at 60 C used for saponification was also confirmed (not shown). LNO 2 -Dependent Vasorelaxation. For both RASMC and aortic segments, LNO 2 addition induced a concentration-dependent increase in cgmp. LNO 2 (50 M) increased the cgmp content of RASMC monolayers and aortic segments to an extent equivalent to that induced by 10 M SNP (Fig. 3 A and B). Isometric tension analysis revealed LNO 2 induced endothelium-independent vasorelaxation, with vehicle (CH 3 OH), the parent fatty acid (18:2), and exposure to light during LNO 2 incubations having no effect (Fig. 4A). L G -nitro-l-arginine methyl ester addition and endothelial denudation did not affect LNO 2 -induced vasorelaxation, revealing that endogenous endothelial NO synthesis was not stimulated by LNO 2 (Fig. 4A). Vascular relaxation induced by LNO 2 was inhibited by the GC inhibitor ODQ and the NO scavenger oxyhemoglobin (oxyhb), indicating the participation of an NO-like species in the vasomotor actions of LNO 2 (Fig. 4B). Fig. 4. LNO 2 stimulates relaxation of rat thoracic aortic rings. LNO 2 (3 30 M) induced significant relaxation of endothelium-intact, endothelium-denuded, and L G -nitro-l-arginine methyl ester-pretreated thoracic aorta rings compared with controls (3 30 M linoleate or equivalent amounts of solvating CH 3 OH added for each lipid concentration used) (A). ODQ (30 M) and oxyhb (10 M) addition significantly reversed LNO 2 (30 M)-induced relaxation of isolated thoracic aorta (B). Data are expressed as mean SEM, n 6, with * representing P 0.05 vs. LNO 2 addition. Discussion Enzymatically oxidized lipid derivatives (eicosanoids) play an indispensable signaling role in diverse tissue compartments and cell types (35 38). Also, the nonenzymatic oxidation of free and esterified arachidonic acid yields isoprostane and isoleukotriene derivatives that contribute to inflammatory signaling and injury processes (39). These isoeicosanoids potently affect vascular, renal, and inflammatory cell function and are produced at increased rates when membrane and lipoprotein lipids are oxidized by reactive inflammatory mediators and xenobiotics including hydroperoxides, ONOO, transition metals, cigarette smoke, photochemical air pollution, and other products of organic combustion (39 42). Oxides of nitrogen have long been recognized to catalyze lipid oxidation and nitration, on the basis of investigations focused on understanding pathologic processes associated with the NO and NO 2 components of cigarette smoke and polluted air (19, 43 45). Also, bioactive isoeicosanoid derivatives have been described in lipid systems exposed to NO 2 and ONOO (40, 41). This foundation of knowledge encourages that oxides of nitrogen may similarly catalyze formation of the nitrated fatty acid signaling species reported herein, yielding a class of diffusible mediators that represent the convergence of eicosanoid, isoeicosanoid, and NO signaling pathways. Since the description of NO as a ubiquitous signaling molecule, there have been a number of linkages reported between eicosanoid and NO signaling pathways. First, there is comodulation of the expression of NO and eicosanoid biosynthetic enzymes, with prostaglandins modulating NO synthase expression and NO modulating prostaglandin H synthase (PGHS) cgi doi pnas Lim et al.

5 expression (46, 47). Also, NO reacts at almost diffusion-limited rates with enzyme-bound lipid peroxyl radical intermediates during eicosanoid metabolism, leading to an inhibition of lipoxygenase- and PGHS-derived eicosanoid formation (48 50). During the PGHS catalytic cycle, NO-derived species can also react with and impair the catalytic function of enzyme tyrosyl radical and heme peroxidase intermediates (51). Conversely, ONOO serves to activate PGHS (47, 51). This interaction of NO and eicosanoid signaling pathways is exemplified by studies of NOS2 / mice, wherein endogenous rates of tissue NO production modulate tissue F 2 -isoprostane, prostaglandin E 2, and thromboxane B 2 levels (52). Concomitantly, the reactions of NO with intermediates of lipoxygenase- and PGHS-dependent eicosanoid synthesis catalytically consume NO to a degree that both platelet and monocyte function are altered (48, 50). The nitrated lipids formed by NO-derived species mediate a combination of direct and camp- and cgmp-dependent signaling actions, depending on cell type and the response variable. LNO 2 potently inhibits neutrophil activation [O 2 production, N-formyl-methionyl-leucyl-phenylalanine (fmlp)-stimulated Ca 2 influx, degranulation, and CD11b expression] via noncgmp-dependent mechanisms (53). Also, LNO 2 inhibits thrombin-mediated platelet aggregation by camp-dependent attenuation of Ca 2 mobilization and phosphorylation of vasodilatorstimulated phosphoprotein at serine 157. This occurs via dual regulation of adenylyl cyclase and phosphodiesterase-3 activities (54). In both platelets and neutrophils, there was no evidence for a mediation of cell responses to LNO 2 by NO- or cgmpdependent mechanisms. In contrast, vascular cells were observed herein to rapidly metabolize LNO 2 to an oxyhb-inhibitable species that activated GC and induced relaxation of aortic rings. Also, the GC inhibitor ODQ prevented LNO 2 -induced vasorelaxation, supporting the precept that a NO or nitrosothiol-like species mediates the vascular actions of LNO 2 (Fig. 4B). Endothelium was not critical for transducing vasoactive actions of LNO 2, because inhibition of NOS and denudation of endothelium revealed similar extents of cgmp elevation and vessel relaxation. The ability of smooth muscle cells to metabolize LNO 2 to a NO-like cgmp-dependent species is distinctive when compared with the platelet and neutrophil signaling actions of LNO 2. Nitrated organic esters, such as urate, glucose, and glycerol derivatives, are at least in part metabolized to NO via the reductase action of mitochondrial aldehyde dehydrogensae (55). Nitrosamines, NONOates, nitrosothiols, nitroprusside, organic nitrites (RONO, e.g., isopentyl nitrite), and vicinal nitrohydroxy-eicosanoid derivatives spontaneously liberate NO in a biological milieu via mechanisms sometimes stimulated by metal centers or thiols (55 58). Because we did not observe spontaneous liberation of NO from LNO 2 in the absence or presence of light or thiols, the present data show a requirement for vascular cell metabolism during tissue generation of NO-like species from the more stable allylic nitro adduct of LNO 2. Synthetic LNO 2 displayed chromatographic elution characteristics similar to the species produced by nitration of linoleate by HNO 2, ONOO, and exposure to a MPO NO 2 H 2 O 2 oxidation system (Fig. 1A and data not shown). Identity of these products as LNO 2 was affirmed by internally consistent mass, IR, and 15 N-NMR spectral properties. MS verified the presence of a parent compound with m z 324 and an MS MS daughter ion of m z 46. The IR spectrum of LNO 2, when compared with that of 18:2, displayed absorbance maxima at 1,334 and 1,522 cm 1, corresponding to the symmetric and asymmetric stretches of the N O bonds of a nitroalkene. No maxima appeared in the 1,610- to 1,680-cm 1 region where the N O bonds of organic nitrites and nitrates would strongly absorb (31). The 15 N-NMR spectrum of LNO 2 had chemical shifts at 3.9 and 4.6 ppm when externally referenced to nitromethane (0 ppm), suggesting the presence of at least two positional isomers. Other related compounds with NO 2 functional groups have shifts between 30 ppm when referenced to nitromethane (34). The presence of the nitrito derivative (LONO) was eliminated, due to the absence of both a characteristic IR spectrum and the expected 15 N-NMR chemical shift at 200 ppm (34). Nitrating species such as NO 2 can react with unsaturated fatty acids by both addition and H-atom abstraction reactions, events that are influenced by NO 2 concentration and solvent polarity (26). Thus, present effort is directed toward the characterization of nitrated lipids of different acyl chain lengths and unsaturation with respect to allylic and nitro orientations, the concomitant presence in some products of hydroxyl, peroxyl, or nitrate ester derivatives, and the purification of specific positional isomers in quantities sufficient for assessing relative bioactivities of key isomers. In this regard, progress has been made in defining the structural characteristics of polyunsaturated acyl esters (e.g., organic-solvated methyl linoleate and methyl arachidonate) exposed to acidic NO 2, pure NO in the presence of oxygen and a wide range of gaseous NO 2 concentrations (25, 26, 44, 45). The in vivo production of nitrated free and esterified fatty acids is expected from the occurrence of multiple pathways for generating nitrating intermediates during cell signaling and inflammatory conditions (6, 59). For example, the generation of nitro derivatives of DNA bases, carbohydrates, free tyrosine, and protein tyrosine residues has been observed in 40 disease processes (59). The parallel discovery of enzymatic pathways mediating the reduction or denitration of protein 3-nitrotyrosine derivatives (60) also infers that regulable signaling events can be a consequence of biomolecule nitration. Determination of the in vivo presence of nitrated fatty acids, while described for human plasma (61), bovine cardiac muscle phospholipids (56), human atherosclerotic lesions, and ischemic reperfused rodent liver (unpublished observations), is challenged by complications induced by extraction procedures and a rapid metabolism of LNO 2 by vascular tissues during preparative procedures. There is also significant risk for artifactual de novo LNO 2 production during acidic extraction or analytical procedures when adventitious NO 2 is present (24, 56, 61). In this regard, it has been observed that ph lipid extraction or analytical conditions is sufficient to stimulate NO 2 -mediated linoleate nitration (24). Once plasma and tissue concentrations of nitrated lipids are better defined, a further challenge exists in the translation of concentration-response observations derived from in vitro studies of LNO 2 signaling to the prediction of in vivo organ-level responses. It is noted that solutions of lipophilic and amphipathic molecules added to in vitro test systems must diffuse through an aqueous milieu and partition into membranes and lipoproteins, as well as bind to hydrophobic regions of target proteins, before exerting signaling actions or undergoing metabolism. In this regard, a strong precedent exists for much greater concentrations of exogenously supplied lipid signaling molecules being required, as compared with endogenous production, for activation of a response element such as the peroxisome proliferator-activated receptor- (62). In summary, a nitrated lipid derivative has been synthesized and purified that is similar in basic structure and chromatographic behavior to nitrated lipid species generated by NO-dependent signaling and inflammatory reactions. The cgmp-dependent vasomotor effects of this derivative in smooth muscle cells reveal that nitrated membrane and lipoprotein lipids can uniquely transduce NO signaling reactions. We have also recently observed antiplatelet and neutrophil-inhibitory actions of LNO 2 that are not exclusively cgmp-dependent (53, 54). These collective properties reveal that nitrated lipids, produced in greater rates and quantities during inflammation, can mediate the attenuation of inflammation or promotion of tissue repair by down-regulation of key signaling elements and events. BIOCHEMISTRY Lim et al. PNAS December 10, 2002 vol. 99 no

6 V.B.O. is supported by the British Heart Foundation and the Wellcome Trust and is a Wellcome Trust RCD Fellow. This work was supported by the National Institutes of Health (RO1-HL64937, RO1-HL 58115, P6-HL58418, and NCI CA13148). 1. Ignarro, L. J. (2000) in Nitric Oxide Biology and Pathobiology, ed. Ignarro, L. J. (Academic, San Diego), pp Moncada, S. & Higgs, A. (1993) N. Engl. J. Med. 329, Ignarro, L. J., Lippton, H., Edwards, J. C., Baricos, W. H., Hyman, A. L., Kadowitz, P. J. & Gruetter, C. A. (1981) J. Pharmacol. Exp. Ther. 218, Liu, X., Miller, M. J. S., Joshi, M. S., Thomas, D. D. & Lancaster, J. R., Jr. (1998) Proc. Natl. Acad. Sci. USA 95, Thomas, D. D., Liu, X., Kantrow, S. P. & Lancaster, J. R., Jr. (2001) Proc. Natl. Acad. Sci. USA 98, Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A. & Freeman, B. A. (1990) Proc. Natl. Acad. Sci. USA 87, Radi, R., Denicola, A., Alvarez, B., Ferrer-Sueta, G. & Rubbo, H. (2000) in Nitric Oxide Biology and Pathobiology, ed. Ignarro, L. J. (Academic, San Diego), pp Rubanyi, G. M., Ho, E. H., Cantor, E. H., Lumma, W. C. & Botelho, P. (1991) Biochem. Biophys. Res. Commun. 181, White, C. R., Brock, T. A., Chang, L., Crapo, J., Briscoe, P., Ku, D., Bradley, W. A., Gianturco, S. H., Gore, J., Freeman, B. A. & Tarpey, M. M. (1994) Proc. Natl. Acad. Sci. USA 91, Tarpey, M. M., Beckman, J. S., Ischiropoulos, H., Gore, J. Z. & Brock, T. A. (1995) FEBS Lett. 364, White, C. R., Moellering, D., Patel, R. P., Kirk, M., Barnes, S. & Darley-Usmar, V. M. (1997) Biochem. J. 328, Skinner, K. A., White, C. R., Patel, R., Tan, S., Barnes, S., Kirk, M., Darley-Usmar, V. & Parks, D. A. (1998) J. Biol. Chem. 273, Napolitano, A., Camera, E., Picardo, M. & d Ischia, M. (2000) J. Org. Chem. 65, Napolitano, A., Camera, E., Picardo, M. & d Ischia, M. (2002) J. Org. Chem. 67, Denicola, A., Batthyany, C., Lissi, E., Freeman, B. A., Rubbo, H. & Radi, R. (2002) J. Biol. Chem. 277, Denicola, A., Souza, J. M., Radi, R. & Lissi, E. (1996) Arch. Biochem. Biophys. 328, Rafikova, O., Rafikov, R. & Nudler, E. (2002) Proc. Natl. Acad. Sci. USA 99, Padmaja, S. & Huie, R. E. (1993) Biochem. Biophys. Res. Commun. 195, Rubbo, H., Radi, R., Trujillo, M., Telleri, R., Kalyanaraman, B., Barnes, S., Kirk, M. & Freeman, B. A. (1994) J. Biol. Chem. 269, O Donnell, V. B., Chumley, P. H., Hogg, N., Bloodsworth, A., Darley-Usmar, V. M. & Freeman, B. A. (1997) Biochemistry 36, Rubbo, H., Radi, R., Anselmi, D., Kirk, M., Barnes, S., Butler, J., Eiserich, J. P. & Freeman, B. A. (2000) J. Biol. Chem. 275, O Donnell, V. B. & Freeman, B. A. (2001) Circ. Res. 88, Denicola, A., Souza, J. M. & Radi, R. (1998) Proc. Natl. Acad. Sci. USA 95, O Donnell, V. B., Eiserich, J. P., Chumley, P. H., Jablonsky, M. J., Krishna, N. R., Kirk, M., Barnes, S., Darley-Usmar, V. M. & Freeman, B. A. (1999) Chem. Res. Toxicol. 12, d Ischia, M. (1996) Tetrahedron Lett. 37, d Ischia, M., Rega, N. & Barone, V. (1999) Tetrahedron 55, Baldus, S., Eiserich, J. P., Mani, A., Castro, L., Figueroa, M., Chumley, P., Ma, W., Tousson, A., White, C. R., Bullard, D. C., et al. (2001) J. Clin. Invest. 108, Eiserich, J. P., Baldus, S., Brennan, M., Ma, W., Zhang, C., Tousson, A., Castro, L., Lusis, A. J., Nauseef, W. M., White, C. R. & Freeman, B. A. (2002) Science 296, Hamaya, T., Tomoda, S., Takeuchi, Y. & Nomura, Y. (1982) Tetrahedron Lett. 23, Seebach, D., Calderari, G. & Knochel, P. (1985) Tetrahedron 41, Silverstein, R. M., Bassler, G. C. & Morrill, T. C. (1991) in Spectrometric Identification of Organic Compounds (Wiley, New York), 5th Ed., pp Finlayson-Pitts, B. J., Sweetman, L. L. & Weissbart, B. (1987) Toxicol. Appl. Pharmacol. 89, Ungnade, H. E. & Smiley, R. A. (1956) J. Inorg. Chem. 21, Webb, G. A. (1993) in Annual Reports on NMR Spectroscopy (Academic, New York), Vol. 25, pp Vane, J. R. & Botting, R. M. (1995) Am. J. Cardiol. 75, 3A 10A. 36. Moncada, S. & Vane, J. R. (1979) Pharmacol. Rev. 30, Davidge, S. T. (2001) Circ. Res. 89, Dusting, G. J., Moncada, S. & Vane, J. R. (1979) Prog. Cardiovasc. Dis. 21, Roberts, L. J., II, & Morrow, J. D. (1997) Biochim. Biophys. Acta 1345, Moore, K. P., Darley-Usmar, V., Morrow, J., Roberts, L. J., II (1995) Circ. Res. 77, Long, N. C., Suh, J., Morrow, J. D., Schiestl, R. H., Murthy, G. G. K., Brain, J. D. & Frei, B. (2001) J. Appl. Physiol. 91, Morrow, J. D., Frei, B., Longmire, A. W., Gaziano, M., Lynch, S. M., Shyr, Y., Strauss, W. E., Oates, J. A. & Roberts, L. J., II (1995) N. Engl. J. Med. 332, Pryor, W. A. & Lightsey, J. W. (1981) Science 214, Gallon, A. A. & Pryor, W. A. (1994) Lipids 29, Gallon, A. A. & Pryor, W. A. (1993) Lipids 28, Tetsuka, T., Daphna-Iken, D., Srivastava, S. K., Baier, L. D., DuMaine, J. & Morrison, A. R. (1994) Proc. Natl. Acad. Sci. USA 91, Goodwin, D. C., Landino, L. M. & Marnett, L. J. (1999) FASEB J. 13, O Donnell, V. B., Coles, B., Lewis, M. J., Crews, B. C., Marnett, L. J. & Freeman, B. A. (2000) J. Biol. Chem. 275, O Donnell, V. B., Taylor, K. B., Parthasarathy, S., Kuhn, H., Koesling, D., Friebe, A., Bloodsworth, A., Darley-Usmar, V. M. & Freeman, B. A. (1999) J. Biol. Chem. 274, Coffey, M. J., Natarajan, R., Chumley, P. H., Coles, B., Thimmalapura, P., Nowell, M., Kuhn, H., Lewis, M. J., Freeman, B. A. & O Donnell, V. B. (2001) Proc. Natl. Acad. Sci. USA 98, Goodwin, D. C., Landino, L. M. & Marnett, L. J. (1999) Drug Metab. Rev. 31, Marnett, L. J., Wright, T. L., Crews, B. C., Tannenbaum, S. R. & Morrow, J. D. (2000) J. Biol. Chem. 275, Coles, B., Bloodsworth, A., Clark, S. R., Lewis, M. J., Cross A. R., Freeman, B. A. & O Donnell, V. B. (2002) Circ. Res. 91, Coles, B., Bloodsworth, A., Eiserich, J. P., Coffey, M. J., McLoughlin, R. M., Giddings, J. C., Lewis, M. J., Haslam, R. J., Freeman, B. A. & O Donnell, V. B. (2002) J. Biol. Chem. 277, Chen, Z., Zhang, J. & Stamler, J. S. (2002) Proc. Natl. Acad. Sci. USA 99, Balazy, M., Iesaki, T., Park, J. L., Jiang, H., Kaminski, P. M. & Wolin, M. S. (2001) J. Pharmacol. Exp. Ther. 299, Barnett, D. J., McAninly, J. & Williams, D. L. H. (1994) J. Chem. Soc. Perkin Trans. 2, Williams, D. L. H. (1996) Transition Met. Chem. 21, Greenacre, S. A. & Ischiropoulos, H. (2001) Free Radical Res. 34, Kamisaki, Y., Wada, K., Bian, K., Balabanli, B., Davis, K., Martin, E., Behbod, F., Lee, Y. & Murad, F. (1998) Proc. Natl. Acad. Sci. USA 95, Lima, E. S., Mascio, P. D., Rubbo, H. & Abdalla, D. S. P. (2002) Biochemistry 41, Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D. & Glass, C. K. (1999) Nature 400, cgi doi pnas Lim et al.